Ligand Pharmaceuticals Inc (LGND)
EBITDA Margin
94.32%
TTM · Period ending:
LGND EBITDA Margin
Latest reported94.32%period ending
Latest reported94.32%period ending
LGND TTM EBITDA Margin (-138.35% → 94.32%)
TTM ebitda margin
High-resolution chart · PNG
LGND ebitda margin history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Margin |
|---|---|
| 94.3179% | |
| 81.0315% | |
| 73.1721% | |
| 39.8319% | |
| -24.4898% | |
| -67.2805% | |
| 24.4057% | |
| 63.7296% | |
| 67.5842% | |
| 133.9067% | |
| 77.234% | |
| 108.2475% | |
| 109.0115% | |
| 100.6392% | |
| 71.113% | |
| 29.2224% | |
| 27.7432% | |
| 24.1053% | |
| 28.9468% | |
| 34.8494% | |
| 27.9739% | |
| 40.7964% | |
| 24.0576% | |
| 31.3507% | |
| 34.3598% | |
| 2.4837% | |
| 727.3931% | |
| 535.6737% | |
| 528.0583% | |
| 415.7354% | |
| 78.4174% | |
| 110.6377% | |
| 82.4004% | |
| 77.7381% | |
| 58.5347% | |
| 52.4072% | |
| 49.8121% | |
| 46.8442% | |
| 50.7878% | |
| 48.6954% | |
| 52.2087% | |
| 51.085% | |
| 43.0715% | |
| 40.5526% | |
| 34.7706% | |
| 34.216% | |
| 36.2087% | |
| 35.1695% | |
| 35.689% | |
| 37.3986% | |
| 38.072% | |
| 34.8019% | |
| 29.2718% | |
| 20.4128% | |
| 9.1436% | |
| 16.2143% | |
| 7.3199% | |
| 10.8982% | |
| 4.3914% | |
| -48.2082% | |
| -97.0477% | |
| -115.2868% | |
| -112.8686% | |
| -63.9196% | |
| -11.6678% | |
| -13.5083% | |
| -18.5635% | |
| -210.1488% | |
| -247.2522% | |
| -275.04% | |
| -341.1971% | |
| -148.1107% | |
| -160.2475% | |
| -235.7269% | |
| -446.4092% | |
| -102.5355% | |
| -72.0979% | |
| -43.7211% | |
| -19.8032% | |
| -20.0872% | |
| -9.8171% | |
| -3.7759% | |
| -5.0666% | |
| -22.9294% | |
| -29.0213% | |
| -38.322% | |
| -40.8325% | |
| -15.3401% | |
| -12.7619% | |
| -7.2651% | |
| -3.4696% | |
| -21.0527% | |
| -22.5958% | |
| -27.314% | |
| -18.3173% | |
| -15.9948% | |
| -14.6083% | |
| -12.6116% | |
| -21.6974% | |
| -45.4671% |